Table1.

Molecular aberrations defining administration of approved targeted agents in different solid tumor diagnoses

Cancer type (alphabetically)	Molecular target	Assessment technique	Molecular aberration	Approved targeted agent (chronologically)
AI: aromatase inhibitor, ALK: anaplastic lymphoma kinase, EGFR: epidermal growth factor receptor, ER: estrogen receptor, FISH: fluorescent in situ hybridization, GIST: gastrointestinal stromal tumor, HER2: human epidermal growth factor receptor 2, IHC: immunohistochemistry, PgR: progesterone receptor, T-DM1: trastuzumab DM1.
Breast cancer	ER and/or PgR	IHC	Overexpression	Tamoxifen, AIs fulvestrant
HER2	IHC FISH	Overexpression and/or amplification	Trastuzumab, lapatinib pertuzumab T-DM1
Colorectal cancer	KRAS	DNA	Mutation	Cetuximab, panitumumab
Gastric cancer	HER2	IHC FISH	Overexpression and/or amplification	Trastuzumab
GIST	KIT	IHC	Mutation	Imatinib
Lung cancer	EGFR	DNA	Mutation	Gefitinib, erlotinib
ALK and/or ROS	FISH	Rearrangement	Crizotinib
RET	FISH	Rearrangement	Vandetanib
Melanoma	BRAF	DNA	Mutation	Vemurafenib, dabrafenib